BioLife Solutions (BLFS) PT Raised to $31 at TD Cowen

TD Cowen analyst Max Masucci raised the price target on BioLife Solutions (NASDAQ: BLFS) to $31.00 (from $28.00) while maintaining a Buy rating.

The analyst commented, "Core revs of $27M beat consensus driven by Cell Processing strength ($19M, +43% y/ y). Mgmt feels the macro environment is largely normalized driving this segment with 80% of revs coming from top-20 pharma. SciSafe sale for $73M highlights commitment to focus on core competency and high margin rev growth. Raising PT to $31 (+$3) on improved strategy, financial profile, and shored up balance sheet."

You May Also Be Interested In

• Constellation Brands (STZ) PT Lowered to $145 at UBS on Softer Consumer Backdrop
• UiPath Inc. (PATH) PT Lowered to $15 at RBC Capital
• KB Home (KBH) PT Lowered to $50 at RBC Capital